Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2

BACKGROUND: This phase Ib study evaluated afatinib plus vinorelbine in patients with advanced solid tumours overexpressing epidermal growth factor receptor (EGFR) and/or human EGFR 2 (HER2). METHODS: Maximum tolerated doses (MTDs) were determined for afatinib (20, 40 or 50 mg, once daily) combined w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Bahleda, Rastislav, Varga, Andrea, Bergé, Yann, Soria, Jean-Charles, Schnell, David, Tschoepe, Inga, Uttenreuther-Fischer, Martina, Delord, Jean-Pierre
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2018
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808039/
https://ncbi.nlm.nih.gov/pubmed/29337963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.436
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados